144 related articles for article (PubMed ID: 10969347)
1. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure.
Balotta C; Violin M; Monno L; Bagnarelli P; Riva C; Facchi G; Berlusconi A; Lippi M; Rusconi S; Clementi M; Galli M; Angarano G; Moroni M
J Acquir Immune Defic Syndr; 2000 Jul; 24(3):232-40. PubMed ID: 10969347
[TBL] [Abstract][Full Text] [Related]
2. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.
Schmit JC; Van Laethem K; Ruiz L; Hermans P; Sprecher S; Sönnerborg A; Leal M; Harrer T; Clotet B; Arendt V; Lissen E; Witvrouw M; Desmyter J; De Clercq E; Vandamme AM
AIDS; 1998 Oct; 12(15):2007-15. PubMed ID: 9814869
[TBL] [Abstract][Full Text] [Related]
3. Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Sirivichayakul S; Ruxrungtham K; Ungsedhapand C; Techasathit W; Ubolyam S; Chuenyam T; Emery S; Cooper D; Lange J; Phanuphak P
AIDS; 2003 Sep; 17(13):1889-96. PubMed ID: 12960821
[TBL] [Abstract][Full Text] [Related]
4. The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Miller V; Stürmer M; Staszewski S; Gröschel B; Hertogs K; de Béthune MP; Pauwels R; Harrigan PR; Bloor S; Kemp SD; Larder BA
AIDS; 1998 May; 12(7):705-12. PubMed ID: 9619801
[TBL] [Abstract][Full Text] [Related]
5. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
Kavlick MF; Wyvill K; Yarchoan R; Mitsuya H
J Infect Dis; 1998 Jun; 177(6):1506-13. PubMed ID: 9607827
[TBL] [Abstract][Full Text] [Related]
6. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Avi R; Pauskar M; Karki T; Kallas E; Jõgeda EL; Margus T; Huik K; Lutsar I
J Med Virol; 2016 Mar; 88(3):448-54. PubMed ID: 26291050
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
9. Structural Insights into HIV Reverse Transcriptase Mutations Q151M and Q151M Complex That Confer Multinucleoside Drug Resistance.
Das K; Martinez SE; Arnold E
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396546
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a cohort of Italian HIV-1 seropositive patients extensively treated with antiretroviral drugs.
Re MC; Borderi M; Monari P; Bon I; Gorini R; Gibellini D; Verucchi G; Fortunato L; Chiodo F; La Placa M
Int J Antimicrob Agents; 2001 Dec; 18(6):519-23. PubMed ID: 11738338
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
Van Vaerenbergh K; Van Laethem K; Albert J; Boucher CA; Clotet B; Floridia M; Gerstoft J; Hejdeman B; Nielsen C; Pannecouque C; Perrin L; Pirillo MF; Ruiz L; Schmit JC; Schneider F; Schoolmeester A; Schuurman R; Stellbrink HJ; Stuyver L; Van Lunzen J; Van Remoortel B; Van Wijngaerden E; Vella S; Witvrouw M; Yerly S; De Clercq E; Destmyer J; Vandamme AM
Antimicrob Agents Chemother; 2000 Aug; 44(8):2109-17. PubMed ID: 10898683
[TBL] [Abstract][Full Text] [Related]
13. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens.
Ross L; Scarsella A; Raffanti S; Henry K; Becker S; Fisher R; Liao Q; Hirani A; Graham N; St Clair M; Hernandez J;
AIDS Res Hum Retroviruses; 2001 Aug; 17(12):1107-15. PubMed ID: 11522180
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.
Quiros-Roldan E; Bertelli D; Signorini S; Airoldi M; Torti C; Moretti F; Carosi G
Microbios; 2001; 106(414):137-45. PubMed ID: 11506064
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
16. A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Rusconi S; La Seta Catamancio S; Sheridan F; Parker D
J Clin Virol; 2000 Dec; 19(3):135-42. PubMed ID: 11090748
[TBL] [Abstract][Full Text] [Related]
17. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs.
de Jong JJ; Goudsmit J; Lukashov VV; Hillebrand ME; Baan E; Huismans R; Danner SA; ten Veen JH; de Wolf F; Jurriaans S
AIDS; 1999 Jan; 13(1):75-80. PubMed ID: 10207547
[TBL] [Abstract][Full Text] [Related]
18. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
Principi N; Marchisio P; Esposito S; Rossi P; Gattinara GC; Galli L; Gabiano C; Zuccotti GV; Orlandi P
AIDS Res Hum Retroviruses; 1998 Dec; 14(18):1653-9. PubMed ID: 9870319
[TBL] [Abstract][Full Text] [Related]
19. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
Pellegrin I; Segondy M; Garrigue I; Izopet J; Montes B; Pellegrin JL; Reynes J; Massip P; Puel J; Fleury H
J Acquir Immune Defic Syndr; 2000 Dec; 25(5):465-6. PubMed ID: 11141248
[No Abstract] [Full Text] [Related]
[Next] [New Search]
